Private equity firm Novalpina Capital completed the acquisition of Laboratoire X.O, the French specialty pharmaceuticals business. Financial terms were not disclosed. "Starting from small beginnings in 2015, I am proud to have grown X.O into a fast-growing niche-player in branded pharmaceuticals. With our strong base in the French market, we see tremendous opportunity for continued growth both in France and internationally. I am impressed by Novalpina Capital’s vision for the business, and I am pleased to continue in partnership with both them and X.O’s excellent management team, as a Board member and investor," Gerard Leduc, Laboratoire X.O Founder.